

Untargeted saliva metabolomics reveals COVID-19 severity

Running head: Saliva Metabolomics for SARS-COV-2 Prognosis

Cecile F. Frampas¹, Katie Longman¹, Matt P. Spick¹, Holly M. Lewis¹, Catia D. S. Costa², Alex Stewart³, Deborah Dunn-Walters³, Danni Greener⁴, George E. Evetts⁴, Debra Skene³, Drupad Trivedi⁵, Andrew R. Pitt⁵, Katherine Hollywood⁵, Perdita Barran⁵ and Melanie J. Bailey^{1,2}

¹ Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, GU2 7XH, UK

² Surrey Ion Beam Centre, University of Surrey, Guildford, GU2 7XH, UK

³ Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7XH, UK

⁴ Frimley Park Hospital, Frimley Health NHS Trust, GU16 7UJ, UK

⁵ Manchester Institute of Biotechnology, University of Manchester, M1 7DN, United Kingdom

Corresponding Author: Dr Melanie Bailey, tel +44 (0)1483 682593, m.bailey@surrey.ac.uk, Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, GU2 7XH, UK

Preprint location: MedRxiv

CF, KL and MS contributed equally to this paper.

Keywords: Saliva, Metabolomics, COVID-19, Prognostic Test, Liquid Chromatography Mass Spectrometry

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Abbreviations**

COVID-19	Coronavirus disease 19
CRP	C-reactive protein
HTN	Hypertension
IHD	Ischemic heart disease
KEGG	Kyoto Encyclopedia of Genes and Genomes
LC	Liquid chromatography
LC-MS	Liquid chromatography mass spectrometry
LOOCV	Leave-one-out cross validation
MS	Mass spectrometry
MS/MS or MS ²	Tandem mass spectrometry
NPA	Negative percent agreement
PCA	Principal components analysis
PCR	Polymerase chain reaction
PLS-DA	Partial least squares-discriminant analysis
PPA	Positive percent agreement
QC	Quality control
RT-PCR	Reverse transcription polymerase chain reaction
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
T2DM	Type 2 diabetes mellitus
VIP	Variable importance in projection

24

25 **ABSTRACT**

26 **Background**

27 The COVID-19 pandemic is likely to represent an ongoing global health issue given
28 the potential for vaccine escape and the low likelihood of eliminating all reservoirs of
29 the disease. Whilst diagnostic testing has progressed at pace, there is an unmet
30 clinical need to develop tests that are prognostic, to triage the high volumes of patients
31 arriving in hospital settings. Recent research has shown that serum metabolomics has
32 potential for prognosis of disease progression. ¹ In a hospital setting, collection of
33 saliva samples is more convenient for both staff and patients, and therefore offers an
34 alternative sampling matrix to serum. We demonstrate here for the first time that saliva
35 metabolomics can reveal COVID-19 severity.

36 **Methods**

37 88 saliva samples were collected from hospitalised patients with clinical suspicion of
38 COVID-19, alongside clinical metadata. COVID-19 diagnosis was confirmed using RT-
39 PCR testing. COVID severity was classified using clinical descriptors first proposed by
40 SR Knight et al. Metabolites were extracted from saliva samples and analysed using
41 liquid chromatography mass spectrometry.

42 **Results**

43 In this work, positive percent agreement of 1.00 between a PLS-DA metabolomics
44 model and the clinical diagnosis of COVID severity was achieved. The negative
45 percent agreement with the clinical severity diagnosis was also 1.00, for overall
46 percent agreement of 1.00.

47 **Conclusions**

48 This research demonstrates that liquid chromatography-mass spectrometry can
49 identify salivary biomarkers capable of separating high severity COVID-19 patients
50 from low severity COVID-19 patients in a small cohort study.

51

52 **1. Introduction**

53 The SARS-CoV-2 pandemic has caused a sustained threat to global health since the
54 discovery of the virus in 2019.² Whilst great strides have been made in both treatment
55 and vaccination development,^{3,4} the disease has inflicted multiple waves of infection
56 throughout the world during 2020 and into 2021.^{5,6} COVID-19 has higher fatality rates
57 than seasonal influenza,⁷ and in addition, new variants are constantly evolving with
58 the potential for either reduced vaccine effectiveness or altered lethality.⁸ As a
59 consequence, there is a continuing need both for better understanding of the impact
60 of COVID-19 on the host metabolism as well as for prognostic tests that can be used
61 to triage the high volumes of patients arriving in hospital settings.

62 Nasopharyngeal swabs followed by polymerase chain reaction (PCR) have been
63 adopted worldwide for SARS-CoV-2 detection. However, supply chains for swabs
64 rapidly collapsed amongst exponential increases in demand for testing, highlighting
65 the urgency for alternative sample types and testing approaches. Furthermore, whilst
66 PCR tests are easily deployable and highly selective for the virus, these approaches
67 yield no prognostic information and cannot easily be delivered for rapid turnaround at
68 the point of care, for example during a hospital admissions process. In contrast, tests
69 based on mass spectrometry can be provided in minutes, with mass spectrometry
70 instrumentation typically available in hospital pathology laboratories. Prognostic tests,
71 whilst challenging due to the varied phenotypes that may present themselves,⁹ could
72 be used to manage demand for hospitalisation and treatment, especially should
73 vaccine escape lead to future waves of COVID-19 infection.

74 Metabolic biomarkers in serum have been identified that carry prognostic information,
75 ^{10,11} but sampling blood is invasive. Our experience in collecting and analysing patient

76 samples is that saliva samples are significantly easier to collect and handle than blood.
77 Blood collection requires trained phlebotomists, causes discomfort to patients and
78 must be spun soon after collection to preserve the metabolome. In contrast, a saliva
79 sample can be donated quickly and painlessly by a patient. Saliva is itself a carrier of
80 the coronavirus, ¹² and has been proposed as a gold standard for SARS-CoV-2
81 detection. ^{13,14} It additionally offers information via its own characteristic metabolites.
82 ¹⁵ To date, saliva as a biofluid for metabolism analysis has been used for breast,
83 pancreatic and also oral cancers. ^{16,17} Here we explore the potential of saliva
84 metabolomics to distinguish between severe and mild COVID-19 infection, with a view
85 to providing a prognostic test that can be used to triage hospital patients, for example
86 to identify patients who would benefit from immunomodulating drugs such as
87 Tocilizumab. ¹⁸

88 This work took place as part of the wider efforts of the COVID-19 International Mass
89 Spectrometry (MS) Coalition. ^{19,20} This consortium aims to provide molecular level
90 information on SARS-CoV-2 in infected humans, in order to better understand,
91 diagnose and treat cases of COVID-19 infection. Data related to this work will be
92 stored and fully accessible on the MS Coalition open repository. The website URL is
93 <https://covid19-msc.org/>

94 **2. Materials and Methods**

95 **2.1 Participant recruitment and ethics**

96 Ethical approval for this project (IRAS project ID 155921) was obtained via the NHS
97 Health Research Authority (REC reference: 14/LO/1221). 88 participants were
98 recruited at NHS Frimley NHS Foundation Trust hospitals by researchers from the
99 University of Surrey. Participants were identified by clinical staff to ensure that they

100 had the capacity to consent to the study, and were asked to sign an Informed Consent
101 Form; those that did not have this capacity or who did not sign the form were not
102 sampled. Consenting participants were categorised by the hospital as either “query
103 COVID” (meaning there was clinical suspicion of COVID-19 infection) or “COVID
104 positive” (meaning that a positive COVID test result had been recorded during their
105 admission). All participants were provided with a Patient Information Sheet explaining
106 the goals of the study.

107 Inclusion for participants was determined by reverse transcription polymerase chain
108 reaction (RT-PCR) results; participants with an inconclusive RT-PCR test (clinically
109 positive only and/or inconclusive test result, n=6) or where the time lag between initial
110 RT-PCR test and sampling exceeded fourteen days were excluded (n=7). These
111 additional exclusion criteria reduced the participant population from 88 to 75.

112 **2.2 Sample collection, extraction and instrumental analysis**

113 Patients were sampled immediately upon recruitment to the study in two waves, one
114 between May and August 2020 and the second between October and November 2020.
115 The range in time between symptom onset and saliva sampling ranged from 1 day to
116 > 1 month, an inevitable consequence of collecting samples in a pandemic situation.
117 Each participant provided a sample of saliva by spitting directly into a falcon tube which
118 was placed on ice immediately after collection. Samples were transferred on ice from
119 the hospital to the University of Surrey by courier within 4 hours of collection, to
120 minimise changes to salivary metabolites. ²¹ Once received at University of Surrey,
121 the samples were stored at minus 80 °C until analysis.

122 Alongside saliva collection, metadata for all participants was also collected covering
123 *inter alia* sex, age, comorbidities (based on whether the participant was receiving

124 treatment), the results and dates of COVID PCR tests, bilateral chest X-Ray changes,
125 smoking status, drug regimen, and whether and when the participant presented with
126 clinical symptoms of COVID-19. Values for lymphocytes, CRP and eosinophils were
127 also taken; values obtained within five days of the saliva sampling were recorded.
128 Each participant was attributed a “severity score” in relation to their fitness
129 observations at the time of hospital admission using the metadata collected. This score
130 used the “mortality scoring” approach of SR Knight *et al.*⁸ adapted to disregard age,
131 sex at birth and comorbidities, and ranged from 0 to 6; patients scoring 0 to 3 were
132 attributed low severity and patients scoring 4 to 6 were attributed high severity.

133 Sample preparation and processing followed the guidelines set out by the COVID-19
134 Mass Spectrometry Coalition.²² Saliva samples were separated into aliquots: 50 µL
135 of saliva was added to 200 µL of ice-cold isopropanol to precipitate protein, and this
136 also had the advantage of deactivating the virus to allow transfer into a lower biological
137 safety level laboratory. The samples were agitated for one hour, sonicated three times
138 for 30 seconds, with resting on ice for 30 seconds between each sonication. Each
139 sample was then left to stand on ice for 30 minutes then centrifuged for 10 minutes at
140 10 000 g. The supernatant was removed and the precipitated protein pellet reserved
141 for future analysis. The supernatant then underwent centrifugal filtration (0.22 µm
142 cellulose acetate) for five minutes at 10,000 g, and the filtered supernatant was then
143 dried under nitrogen and stored at minus 80 °C.

144 Samples were reconstituted on the day of analysis in 100 µL water:methanol (95:5)
145 with 0.1% formic acid by volume. 10 µL of each sample was set aside for combination
146 into a pooled QC. The samples were analysed over a period of eleven days. Each day
147 consisted of a run incorporating blank injections (n=2), field blank injections (n=3),
148 pooled QC injections (n=6, 3 at the start and finish), as well as QCs to measure

149 instrumental and extraction variation (n=7 and 3 respectively), and 10 participant
150 samples, randomised for positive/negative, with 3 repeat analyses for each.

151 **2.3 Materials and chemicals**

152 The materials and solvents utilised in this study were as follows: 2 mL microcentrifuge
153 tubes (Eppendorf, UK), 0.22 μm cellulose acetate sterile Spin-X centrifuge tube filters
154 (Corning incorporated, USA), 200 μL micropipette tips (Starlab, UK) and Qsert™ clear
155 glass insert LC vials (Supelco, UK). LC-MS grade 2-propanol was used as an
156 inactivation solvent. Optima™ LC-MS grade methanol and water were used as
157 reconstitution solvents and mobile phases. LC-MS grade formic acid was added to the
158 mobile phase solvents at 0.1% (v/v). Solvents were purchased from Fisher Scientific,
159 UK.

160 **2.4 Instrumentation and operating conditions**

161 Analysis of samples was carried out using a UltiMate 3000 UHPLC equipped with a
162 binary solvent manager, column compartment and autosampler, coupled to a Q
163 Exactive™ Plus Hybrid Quadrupole-Orbitrap™ mass spectrometer (Thermo Fisher
164 Scientific, UK) at the University of Surrey's Ion Beam Centre. Chromatographic
165 separation was performed on a Waters ACQUITY UPLC BEH C18 column (1.7 μm ,
166 2.1 mm x 100 mm) operated at 55 °C with a flow rate of 0.3 ml min⁻¹.

167 Mobile phase A was water: methanol (v/v 95:5) with 0.1% formic acid, whilst mobile
168 phase B was methanol:water (v/v, 95:5) with 0.1% formic acid (v/v). An injection
169 volume of 5 μL was used. The initial solvent mixture was 2% B for one minute,
170 increasing to 98% B over 16 minutes and held at this level for four minutes. The
171 gradient was finally reduced back to 2% B and held for two minutes to allow for column
172 equilibration. Analysis on the Q-Exactive Plus mass spectrometer was performed with

173 a scan range of m/z 100 to 1 000, and 5 ppm mass accuracy. MS/MS validation of
174 features was carried out on Pooled QC samples using data dependent acquisition
175 mode and normalised collision energies of 30 and 35 (arbitrary units). Operating
176 conditions are summarised in Table S1 (Supplementary Material).

177 **2.5 Data processing**

178 LC-MS outputs (.raw files) were pre-processed for alignment and peak identification
179 using Compound Discoverer version 3.1 and Freestyle 1.6 (Thermo Fisher Scientific,
180 UK). Peak picking was set to a mass tolerance ± 5 ppm, and alignment to a retention
181 time window of 120 seconds. Missing values were imputed using a K-nearest
182 neighbour approach.²³ Features identified by mass spectrometry were initially
183 annotated using accurate mass match with reference to external databases (KEGG,
184 Human Metabolome Database, DrugBank, LipidMaps and BioCyc), and then
185 validation was performed using data dependent MS/MS analysis. This process yielded
186 an initial peak:area matrix with 10,700 discrete features. Two criteria were used for
187 inclusion in the final analysis: only those features with identities validated by MS/MS
188 were used, reducing the number of features to 1,874, and 1,514 features that were
189 present in less than 30% of participant samples were excluded. This left 360 features
190 that were used in the analysis. Normalisation was performed using EigenMS in
191 NOREVA for each dataset analysed,^{24,25} i.e. independently for the diagnostic
192 population (COVID-19 positive versus negative) and prognostic population (COVID-
193 19 positive: high severity versus low severity).

194 **2.6 Statistical Analysis**

195 PCA analyses were conducted in SIMCA (Sartorius Stedim Biotech, France). PLS-DA
196 and additional machine learning was conducted in R Studio Version 1.3.959 and

197 MetaboAnalyst.^{26,27} Leave-one-out cross-validation was used for model validation test
198 accuracy, sensitivity and specificity; variable importance in projection (VIP) scores
199 were used to assess feature significance alongside p-values and effect sizes (fold
200 count). Batch effects were assessed by PCA analysis of both collection batches
201 (waves one and two) and also instrument and extraction batching by day (Figures S1
202 and S2, Supplementary Material), showing no clustering by batches. KEGG pathway
203 analysis was performed using MetaboAnalyst.

204 In prognostic analysis, given the lack of a “gold standard” reference test for whether
205 COVID-19 is likely to be high severity or low severity (as this depends on clinical
206 judgement), positive percent agreement (PPA) between the generated model and a
207 high severity clinical diagnosis was used in preference to sensitivity, which measures
208 the detection of positive instances of a disease relative to a ground truth value.
209 Similarly, negative percent agreement (NPA) between the model and a high severity
210 clinical diagnosis was used in preference to specificity, which measures the absence
211 of a disease relative to a ground truth value. In diagnostic analysis, given that RT-PCR
212 tests were available to establish a ground truth, sensitivity and specificity values were
213 calculated alongside diagnostic accuracy.

214 **3. RESULTS**

215 **3.1 Population metadata overview**

216 The study population analysed in this work included 75 participants, comprising 47
217 participants presenting with a positive COVID-19 RT-PCR test and 28 participants
218 presenting without. Of the positive participants, 10 were classed as presenting with
219 high severity COVID-19, 34 were classed as presenting with low severity COVID-19,

220 and 3 lacked sufficient clinical information for severity scoring. A summary of the
 221 metadata is shown in Table 1.

222 **Table 1:** Summary of clinical characteristics by participant cohort

Parameters	Covid-19 Low severity	Covid-19 High severity	p-value High vs Low Severity	Covid-19 Negative	p-value Pos vs Neg
n	34	10		28	
Age (mean, standard deviation; years)	59.7 ± 18.4	63.1 ± 12.7	0.61	61.6 ± 21.9	0.74
Male / Female (n)	16 / 18	8 / 2	0.083	16 / 12	0.26
Treated for Hypertension (n)	6	6	.041	12	0.21
Treated for High Cholesterol (n)	2	0	1.00	6	.05
Treated for Type 2 Diabetes Mellitus (n)	5	3	0.39	10	0.29
Treated for Ischemic Heart Disease (n)	1	2	0.149	7	0.09
Current Smoker (n)	1	0	1.00	0	NA
Ex-Smoker (n)	12	5	0.71	8	0.46
Medical Acute Dependency admission (n)	10	6	0.26	4	0.06
Intensive Care Unit admission (n)	0	0	N/A	0	NA
Survived Admission (n)	34	8	0.048	27	1.00
Lymphocytes (mean, standard deviation; cells / μ L)	0.8 ± 0.5	0.9 ± 0.7	0.77	1.0 ± 0.5	0.302
C-Reactive Protein (mean, standard deviation; mg / L)	115.4 ± 84.9	170.0 ± 83.4	0.075	127.3 ± 104.7	0.80
Eosinophils (mean, standard deviation; 100 / μ L)	0.1 ± 0.1	0.0 ± 0.0	0.018	0.3 ± 0.4	0.002
Bilateral Chest X-Ray changes (n)	15	8	0.26	3	0.0009
Continuous Positive Airway Pressure (n)	1	1	0.442	3	0.36
O ₂ required (n)	9	4	0.69	8	1.00

223
 224 In this study all participants were recruited in a hospital setting with at least potential
 225 suspicion of COVID-19 infection; controls were age matched and had similar profiles
 226 in terms of gender, oxygen requirements and survival rates. Significantly more COVID-
 227 19 positive patients had bilateral chest X-ray changes (p-value 0.0009) and higher
 228 levels of eosinophils (p-value 0.002), in agreement with literature observations,¹⁰ but
 229 not for C-reactive protein (CRP, p-value 0.80). Type 2 diabetes mellitus (T2DM) was
 230 more prevalent in the COVID-19 negative population than the positive population,
 231 being observed in 36% of COVID-19 negatives versus 30% of high severity COVID-

232 19 patients and 15% of low severity COVID-19 patients, and a similar observation of
233 greater comorbidity being seen in the negative population was also true for ischemic
234 heart disease (IHD) and hypertension (HTN). The greater preponderance of
235 underlying comorbidities within the negative population represents a confounding
236 factor.

237 Within the COVID-19 positive cohort, comorbidities were again age matched, but the
238 high severity grouping had more males (80% male for high severity versus 47% for
239 low severity) and had a statistically significant difference in proportion presenting with
240 hypertension (p-value 0.04) and a statistically significant decrease in eosinophil levels
241 (p-value 0.02). CRP was increased by a 1.5x fold count in high severity participants
242 versus low (p-value 0.08). There was no statistically significant increase in CRP for
243 low severity versus COVID-19 negative participants, but this may reflect changes to
244 the inflammatory response caused by interventions reducing CRP levels in cases of
245 mild COVID-19.


246 **3.2 Overview of features identified by Liquid Chromatography Mass** 247 **Spectrometry (LC-MS)**

248 360 features with MS/MS validation were identified as being present in 30% or more
249 of participant samples. Of these 360 features, 37 were identified as related to medical
250 interventions or food and were excluded, leaving 323 for statistical analysis. Of the
251 323, 38 were annotated by *m/z* value, 171 were annotated by formula (elemental
252 composition), and 114 were annotated as metabolites.

253 **3.3 Analysis of cohorts by multivariate techniques**

254 Initially separation of COVID-19 positive versus negative participants was tested, as
255 well as separation of COVID-19 high severity and low severity. As shown in Figure 1A,

256 separation for diagnostic purposes showed no clear separation by visual inspection
 257 and delivered R²_Y of 0.78 and Q²_Y of 0.18. Leave-one-out cross-validation (LOOCV)
 258 provided sensitivity of 0.74 (95% confidence interval of 0.60 - 0.86) and specificity of
 259 0.75 (0.55 - 0.89), which was considered insufficient to justify further investigation. The
 260 most significantly dysregulated identified metabolites (measured by p-value) between
 261 positive and negative COVID-19 status are listed in table S2 (Supplementary Material).
 262 Figure 1B shows separation for COVID-19 high severity participants versus low
 263 severity participants. The optimal separation was found using 5 components. Using
 264 leave-one-out cross validation, PPA for COVID-19 high severity was 1.00 (95%
 265 confidence interval of 0.69 - 1.00) and NPA was 1.00 (0.90 - 1.00), for overall percent
 266 agreement with the clinical diagnosis of 1.00 (0.92 - 1.00).



267
 268 **Figure 1:** Saliva metabolomics analysis for COVID-19 diagnosis and prognosis via
 269 LC-MS, showing:

270 **A** PLS-DA plot for 75 participants, COVID-19 positive / negative


271 **B** PLS-DA plot for 44 participants, high severity / low severity

272 C LOOCV confusion matrix, COVID-19 positive / negative

273 D LOOCV confusion matrix, high severity / low severity


274

275 A volcano plot is shown in Figure 2. The most significantly dysregulated identified
276 metabolites (measured by p-value) are shown as boxplots in Figure 3 below and a
277 complete list of metabolites showing statistically significant differences between high
278 and low COVID severity populations is shown in table S3 (Supplementary Material).
279 Amino acids are highlighted as this class of metabolites was the most dysregulated
280 between high and low severity of the identified features.



281

282 **Figure 2:** Volcano plot of statistical significance versus effect size for MS/MS validated
283 features separating participants presenting with high severity versus low severity
284 COVID-19



285

286 **Figure 3:** Boxplots of features down regulated with Covid-19 severity

287 [corresponding p-values: 0.066 ; 0.004 ; 0.051]

288

289 MS/MS spectra for the significant features presented in Figure 3 are additionally
290 shown in Figures S3 to S5 (Supplementary Material).

291 The normalised prognostic dataset was also processed for pathway analysis to
292 explore changes in metabolic pathways relating to COVID-19 (Figure S6). No
293 pathways met the criteria for both meaningful impact and statistical significance,
294 possibly due to the number features identified in each pathway being notably smaller
295 than typically achieved in serum or plasma, consistent with saliva being a filtrate and
296 in general featuring lower metabolic concentrations. ²⁸

297 **3.4 Validation set**

398 Whilst no fully independent prognostic validation set was available, it was decided to
399 project the PLS-DA model obtained for high severity versus low severity participants
300 on to COVID-19 negative participants. Given that these participants should not show
301 features associated with high severity COVID-19, this was considered to offer
302 additional information. The confusion matrix for the results of the projection is shown
303 in Table 2 below.

304 **Table 2:** Confusion matrix for PLS-DA model projected on to COVID-19 negative
305 participants

	COVID-19 negative participants
PLS-DA model result: High Severity	1
PLS-DA model result: Low Severity	27

306

307 4. Discussion

308 Whilst age and recruitment venue were well matched (all participants were recruited
309 in a hospital setting including controls), a number of variables within the metadata
310 illustrate the natural difficulties in experimental design experienced during a pandemic.
311 Age ranges of participants were large, a wide range of comorbidities were present,
312 and the time between symptom onset and saliva sampling ranged from 1 day to > 1
313 month. Participant recruitment of the most severely affected was limited by ethics
314 approval only covering patients who could give informed consent, thereby precluding
315 the participation of patients with the highest COVID severity. Furthermore, given the
316 small n in this pilot study, precision was necessarily low and confidence intervals wide.
317 In this study, saliva samples were provided under conditions that could be practically
318 achieved in a hospital pandemic setting, albeit this meant no scope for abstinence
319 from food and / or drink before saliva sampling, and no prior rinsing of the mouth,

320 leading to potential confounding factors. Separation of COVID-19 positive COVID-19
321 versus negative participants was limited, possibly due to COVID-19 negative
322 participants also being hospitalised and in poor health, perhaps having similar
323 inflammatory responses to some COVID-19 positive participants. In spite of this,
324 superior differentiation by multivariate analysis was achieved in relation to COVID-19
325 severity. PLS-DA showed separation of High Severity COVID-19 positive participants
326 from Low Severity COVID-19 positive participants, with PPA and NPA of 100% by
327 LOOCV. Furthermore, whilst not a true independent validation set, projecting the PLS-
328 DA model on to COVID-19 negative participants, i.e. the controls, showed that the
329 model classified them with 97% consistency as “low risk”, i.e. that the features
330 associated with high severity were present neither in low severity nor in COVID-19
331 negative participants.

332 A number of identified metabolites showed statistically significant differences between
333 the high and low severity participants. Both valine (p-value 0.02, fold-count 0.48) and
334 leucine (p-value 0.04, fold-count 0.67) showed statistically significant changes
335 between high and low severity. As shown in Figure 3, amino acids constituted the
336 class of metabolites seeing the most change between high and low severity, similar to
337 literature observations of changes in either amino acids or ratios of amino acids, albeit
338 specific amino acids commonly cited in the literature (for example kynurenine, arginine
339 or ratios thereof) ^{1,29,30} did not feature in the saliva analysis presented here. It should
340 be noted, however, that the correlation of metabolites between saliva and blood has
341 previously been found to be weak or in some cases non-existent, ^{31,32} and the same
342 may be true for the saliva and blood of individuals testing positive for COVID-19. Direct
343 analysis of paired blood samples would be required to draw any definitive conclusion
344 on differential dysregulation of metabolites between serum and saliva.

345 **5. Conclusion**

346 In this work a number of features have been identified for the first time that may
347 differentiate the saliva of those presenting with high severity and low severity COVID-
348 19. We believe that saliva has potential to add to understanding of the progression
349 and severity of COVID-19. In addition, saliva may be collected less invasively than
350 other biofluids, and mass spectrometry techniques have the advantage of being often
351 located within hospitals, making MS-based techniques useful in a clinical setting.
352 Consequently, we view saliva as a worthy biofluid for consideration for prognostic
353 testing.

354 **Data sharing statement**

355 Participant metadata data with identifiers, alongside peak:area matrices used in this
356 work will be made available on the Mass Spectrometry Coalition website upon
357 publication of this study. The analytical protocols used as well as mass spectrometry
358 .raw files, sample and participant data will be openly available for all researchers to
359 access. The website URL is <https://covid19-msc.org/>

360 **Declaration of Competing Interest**

361 The authors have no competing interest to declare.

362 **Author's contributions**

363 CF and KL collected and extracted all samples used in this work, were responsible for
364 LC-MS method development, data processing and statistical analysis in SIMCA. MS
365 conducted machine learning and pathway analyses and additionally drafted the
366 manuscript. CC and HL supported mass spectrometry method development and
367 advised on analytical methods. AS and DDW obtained ethical approval and biobanking

368 of samples. GE and DG facilitated access to participants and collected participant
369 metadata. DS, DT, PB, KH and AP supported experimental and statistical design and
370 also provided editorial comment on the draft manuscript. MB oversaw all aspects of
371 this work, including obtaining funding for the study, clinical access, experimental
372 design, analysis and was responsible for supervision of the research team.

373 **Funding**

374 The authors would like to acknowledge funding from the EPSRC Impact Acceleration
375 Account for sample collection and processing, as well as EPSRC Fellowship Funding
376 EP/R031118/1, the University of Surrey and BBSRC BB/T002212/1. Mass
377 Spectrometry was funded under EP/P001440/1.

378 **Acknowledgements**

379 The authors acknowledge Samiksha Ghimire from Groningen Medical School for
380 translation of participant information sheets and consent forms into Nepalese, as well
381 as Kyle Saunders of the University of Surrey for access to batch controls. The authors
382 are additionally grateful to Thanuja Weerasinge (Jay), Manjula Meda, Chris Orchard
383 and Joanne Zamani of Frimley Park NHS Foundation Trust for their help with ethics
384 approvals and access to hospital patients.

385

386 **Supplementary Material**

387 **Table S1:** Operating conditions of the mass spectrometer used in this research.

Parameter	Operating condition
Spray voltage	3.5 kV
Capillary temperature	275 °C
S-lens RF level	50
Sheath gas flow rate	40
Aux gas flow rate	0
Scan range	100 <i>m/z</i> to 1 000 <i>m/z</i>
Resolution	70 000
Polarity	Positive
AGC target	10 ⁶
Maximum inject time	200


MS/MS Parameter	Operating condition
Mode	Full Scan MS / dd-MS ² with inclusion lists
Resolution	35 000 at <i>m/z</i> 200
Loop Count	6
Intensity threshold	5 * 10 ⁴
Collision energy	30 and 35
Dynamic Exclusion	5 seconds

388

389


390

391



392

393 **Figure S1:** Principal Component Analysis of each patient sample (circles) and batch
394 QC's (squares), coloured according to extraction batch, showing no significant
395 clustering of patient samples according to extraction batch (square: QC ; circle:
396 patients)



397

398 **Figure S2:** Principal Component Analysis of each patient sample and run QC,
 399 showing low levels of QC variation according to position in the run sequence

400 **Table S2:** Features distinctive between COVID-19 positive and negative

Feature	Fold Count	p-value
C25 H36 N6 O6	0.52	0.0121
DL-Phenylalanine	1.39	0.0164
C7 H10 N6 O2	1.35	0.0179
2-linoleoyl-sn-glycero-3-phosphoethanolamine	1.85	0.0180
C39 H71 N2 O16 P3	0.81	0.0226
DC2810000	1.60	0.0231
179.8965	2.09	0.0251
1-Hexadecanoylpyrrolidine	1.84	0.0287
Taurine	1.44	0.0292
2707	1.19	0.0363
148.0048	0.70	0.0379
C47 H84 N9 O13 P3	0.73	0.0415
C22 H36 N8 O9	1.39	0.0439


3721	1.70	0.0443
butyl acrylate	1.62	0.0470
C2 H3 N3 O2 P2	1.25	0.0501

401


402 **Table S3:** Features distinctive between COVID-19 high severity and low severity

Feature	Fold Count	p-value
C44 H74 N8 O16	0.50	0.0000
C39 H67 N7 O15	0.55	0.0003
C29 H56 N7 O11 P	0.57	0.0013
C42 H72 N8 O17	0.54	0.0038
C49 H81 N9 O17	0.61	0.0148
C37 H67 N6 O12 P3	0.51	0.0160
C47 H84 N9 O13 P3	0.66	0.0178
Valine	0.48	0.0198
C6 H13 N2 O6 P	1.92	0.0237
C9 H21 N O6	2.17	0.0241
C17 H22 N4 O8	1.98	0.0247
C8 H12 O5 P2	2.34	0.0254
C2 H8 O5 P2	1.41	0.0258
C60 H86 N10 O9 P2	0.65	0.0270
C32 H48 N8 O9	0.47	0.0289
Lys-phe	0.48	0.0367
N-{3-[(4-Acetamidobutyl)amino]propyl}acetamide	0.59	0.0382
Leucine	0.67	0.0405
C42 H71 N7 O15	0.44	0.0453
273.86553	1.29	0.0475


403



405 **Figure S3:** MS/MS spectra of proline




407 **Figure S4:** MS/MS spectra of valine



409 **Figure S5:** MS/MS spectra of phenylalanine

410



411

412 **Figure S6:** Pathways analysis of metabolites : high severity versus low severity

413

414 **References**

- 415 1 Danlos F-X, Grajeda-Iglesias C, Durand S, *et al.* Metabolomic analyses of
416 COVID-19 patients unravel stage-dependent and prognostic biomarkers. *Cell*
417 *Death Dis* 2021; **12**: 258.
- 418 2 WHO. Novel Coronavirus – China. 2020. [https://www.who.int/csr/don/12-](https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/)
419 [january-2020-novel-coronavirus-china/en/](https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/) (accessed July 27, 2020).
- 420 3 Africa S. Comment Oxford – AstraZeneca COVID-19 vaccine efficacy. 2021;
421 **397**: 174–6.
- 422 4 The RECOVERY Collaborative Group. Dexamethasone in Hospitalized

- 423 Patients with Covid-19 — Preliminary Report. *N Engl J Med* 2020.
- 424 DOI:10.1056/nejmoa2021436.
- 425 5 Cacciapaglia G. Second wave COVID - 19 pandemics in Europe : a temporal
426 playbook. *Sci Rep* 2020; : 1–8.
- 427 6 Lai JW, Cheong KH. Superposition of COVID-19 waves , anticipating a
428 sustained wave , and lessons for the future. 2020; : 1–12.
- 429 7 Piroth L, Cottenet J, Mariet A-S, *et al.* Comparison of the characteristics,
430 morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide,
431 population-based retrospective cohort study. *Lancet Respir Med* 2020; **2600**:
432 1–9.
- 433 8 WHO. SARS-CoV-2 Variant – United Kingdom of Great Britain and Northern
434 Ireland. 2020. <https://www.who.int/csr/don/21-december-2020-sars-cov2-variant-united-kingdom/en/> (accessed Jan 25, 2021).
- 435
- 436 9 Darmon M, Dumas G. Anticipating outcomes for patients with COVID-19 and
437 identifying prognosis patterns. *Lancet Infect Dis* 2021; **21**: 744–5.
- 438 10 Knight SR, Ho A, Pius R, *et al.* Risk stratification of patients admitted to
439 hospital with covid-19 using the ISARIC WHO Clinical Characterisation
440 Protocol: development and validation of the 4C Mortality Score. *BMJ* 2020;
441 **370**: m3339.
- 442 11 Shen B, Yi X, Sun Y, *et al.* Article Proteomic and Metabolomic
443 Characterization of COVID-19 Patient Sera II Article Proteomic and
444 Metabolomic Characterization of COVID-19 Patient Sera. 2020; : 59–72.
- 445 12 To KK, Tsang OT, Yip CC, *et al.* Consistent Detection of 2019 Novel

- 446 Coronavirus in Saliva. 2020; **71**: 841–3.
- 447 13 Costa G, Pereira CM, Kelly T, Valente AP. Saliva NMR-Based Metabolomics
448 in the War Against COVID-19. 2020. DOI:10.1021/acs.analchem.0c04679.
- 449 14 Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. Saliva as a gold-standard
450 sample for SARS-CoV-2 detection. *Lancet Respir Med* 2021.
451 DOI:10.1016/S2213-2600(21)00178-8.
- 452 15 Mandel ID. The Functions of Saliva. *J Dent Res* 1987; **66**: 623–7.
- 453 16 Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary
454 electrophoresis mass spectrometry-based saliva metabolomics identified oral,
455 breast and pancreatic cancer-specific profiles. *Metabolomics* 2010; **6**: 78–95.
- 456 17 Assad DX, Acevedo AC, Cançado E, *et al.* Using an Untargeted Metabolomics
457 Approach to Identify Salivary Metabolites in Women with Breast Cancer. 2020;
458 : 1–13.
- 459 18 Janik E, Niemcewicz M, Podogrocki M, Saluk-Bijak J, Bijak M. Existing Drugs
460 Considered as Promising in COVID-19 Therapy. *Int J Mol Sci* 2021; **22**: 5434.
- 461 19 Struwe W, Emmott E, Bailey M, *et al.* The COVID-19 MS Coalition—
462 accelerating diagnostics, prognostics, and treatment. *Lancet* 2020; **395**: 1761–
463 2.
- 464 20 Spick M, Longman K, Frampas C, *et al.* Changes to the sebum lipidome upon
465 COVID-19 infection observed via rapid sampling from the skin.
466 *EClinicalMedicine* 2021; : 100786.
- 467 21 Duarte D, Castro B, Pereira JL, Marques JF, Lu A, Gil AM. Evaluation of Saliva
468 Stability for NMR Metabolomics : Collection and Handling Protocols. ; : 1–15.

- 469 22 COVID-19 Mass Spectrometry Coalition. COVID-19 metabolomics and
470 lipidomics protocol. 2020. [https://covid19-msc.org/metabolomics-and-](https://covid19-msc.org/metabolomics-and-lipidomics-protocol/)
471 [lipidomics-protocol/](https://covid19-msc.org/metabolomics-and-lipidomics-protocol/) (accessed Jan 25, 2021).
- 472 23 Beretta L, Santaniello A. Nearest neighbor imputation algorithms: A critical
473 evaluation. *BMC Med Inform Decis Mak* 2016; **16**. DOI:10.1186/s12911-016-
474 0318-z.
- 475 24 Karpievitch Y V, Taverner T, Adkins JN, *et al*. Normalization of peak intensities
476 in bottom-up MS-based proteomics using singular value decomposition.
477 *Bioinformatics* 2009; **25**: 2573–80.
- 478 25 Li B, Tang J, Yang Q, *et al*. NOREVA: Normalization and evaluation of MS-
479 based metabolomics data. *Nucleic Acids Res* 2017; **45**: W162–70.
- 480 26 R Core Team. R: A Language and Environment for Statistical Computing.
481 2020. <https://www.r-project.org/>.
- 482 27 Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for Comprehensive and
483 Integrative Metabolomics Data Analysis. *Curr Protoc Bioinforma* 2019; **68**: e86.
- 484 28 Rossini EL, Milani MI, Lima LS, Pezza HR. Paper microfluidic device using
485 carbon dots to detect glucose and lactate in saliva samples. *Spectrochim Acta*
486 *Part A Mol Biomol Spectrosc* 2021; **248**: 119285.
- 487 29 Thomas T, Stefanoni D, Reisz JA, *et al*. COVID-19 infection alters kynurenine
488 and fatty acid metabolism, correlating with IL-6 levels and renal status. *JCI*
489 *Insight* 2020; **5**. DOI:10.1172/jci.insight.140327.
- 490 30 Fraser DD, Slessarev M, Martin CM, *et al*. Metabolomics Profiling of Critically
491 Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and

- 492 Prognostic Biomarkers. *Crit Care Explor* 2020; **2**: e0272.
- 493 31 Do KT, Kastenmüller G, Mook-Kanamori DO, *et al.* Network-Based Approach
494 for Analyzing Intra- and Interfluid Metabolite Associations in Human Blood,
495 Urine, and Saliva. *J Proteome Res* 2015; **14**: 1183–94.
- 496 32 Bel'skaya L V, Sarf EA, Kosenok VK. Age and gender characteristics of the
497 biochemical composition of saliva: Correlations with the composition of blood
498 plasma. *J Oral Biol Craniofacial Res* 2020; **10**: 59–65.
- 499